Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Le Tourneau, Christophe ^a,b,c   Hoimes, Christopher ^d   Zarwan, Corrine ^e   Wong, Deborah J ^f   Bauer, Sebastian ^g   Claus, Rainer ^h,i   Wermke, Martin ^j   Hariharan, Subramanian ^k   Von Heydebreck, Anja ^l   Kasturi, Vijay ^m   Chand, Vikram ⁿ   Gulley, James L ^o  

^a INSTITUT CURIE   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c INSERM   (France)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ Clinical Center Augsburg   (Germany)

^j DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^k PFIZER INC   (United States)

^l MERCK KGAA   (Germany)

^m EMD SERONO INC   (United States)

ⁿ EMD Serono Research Institute   (United States)

^o NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Adrenocortical carcinoma; Avelumab; JAVELIN solid tumor; Neuroendocrine tumors; PD L1; Phase 1

Indexed keywords

ALANINE AMINOTRANSFERASE; AVELUMAB; DIPHENHYDRAMINE; MITOTANE; PARACETAMOL; MONOCLONAL ANTIBODY;

ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DISEASE EXACERBATION; FATIGUE; FEMALE; FEVER; HISTOLOGY; HUMAN; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY;

ADRENOCORTICAL CARCINOMA; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 85055137834     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0424-9     Document Type: Article

References (34)

1. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872-8.
2. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723-36.
3. Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. Cancer Res. 2016;76:3767-72.
4. Assié G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007;92:148-54.
5. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243-50.
6. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer-staging system: a North American validation. Eur J Cancer. 2010;46:713-9.
7. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine Tumors. V3. 2017. https://www.nccn.org/professionals/physician-gls/pdf/neuroendocrine.pdf. Accessed 15 Mar 2018.
8. Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015;3:45.
9. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
10. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207-12.
11. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32-8.
12. Fay AP, Signoretti S, Callea M, Teló GH, McKay RR, Song J, et al. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015;3:3.
13. Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18:587-98.
14. Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148-57.
15. + tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016;11:1993-2005.
16. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374-85.
17. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017;18:599-610.
18. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35:2117-24.
19. Bavencio (avelumab) [package insert]. Rockland, MD: EMD Serono, Inc; 2017.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
21. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20.
22. Cavalcante L, Carneiro BA, Costa RLB, Chae YK, Rademaker A, Giles FJ. Preliminary results from a phase II study of nivolumab for patients with metastatic adrenocortical carcinoma (ACC). J Clin Oncol. 2017;35(Suppl 7S:abstract):96.
23. Habra MA, Campbell M, Jimenez C, Karp D, Hong D, Subbiah V, et al. Efficacy of pembrolizumab (MK-3475) in patients with adrenocortical carcinoma. J Immunother Cancer. 2017;5(Suppl 2:abstract):P424.
24. Tacon LJ, Prichard RS, Soon PS, Robinson BG, Clifton-Bligh RJ, Sidhu SB. Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist. 2011;16:36-48.
25. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189-97.
26. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17:445-53.
27. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497-508.
28. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426-35.
29. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93:2057-62.
30. Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162:349-56.
31. Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166:451-8.
32. O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014;99:1291-7.
33. Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pöllinger A, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97:3495-503.
34. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108:826-30.